Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen is delaying its first quarter financial results until Monday, 23 April so it can include data from an ongoing trial evaluating its anemia drug Aranesp.
Subscribe to our email newsletter
The company initially planned to report first quarter earnings on April 19 but has postponed the announcement to incorporate results of the Aranesp study in small cell lung cancer patients receiving chemotherapy.
Concerns have been raised about drugs like Aranesp, that they may spur the growth of tumors in cancer patients.
Amgen also said its chief financial officer has resigned, sending the company's shares down. Amgen said Richard Nanula was leaving the company to pursue other opportunities and would be replaced by Robert Bradway as executive vice president and chief financial officer.